BioNTech stock crumbled Tuesday after the cofounders of the German biotech announced their plan to step down.

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

Nothing about the recent past, present, or foreseeable future seems all that compelling.

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounder ...

BioNTech (BNTX) stock tumbles 17% after reporting Q4 losses, missing 2026 revenue projections, and announcing co-founder departures. Full analysis here.

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...

In BioNTech’s search for a new CEO—following the announcement earlier Tuesday that Uğu | Leerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife, and CMO Özlem Türeci, to ...

Investors in BioNTech faced a one-two punch of negative developments, sending the company's stock tumbling approximately 19% to a fresh 52-week low. The double blow consisted of a disappointing ...

The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...